ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 157 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $291,000 | -7.0% | 6,601 | +4.1% | 0.00% | – |
| Q1 2021 | $313,000 | +17.2% | 6,343 | 0.0% | 0.00% | – |
| Q4 2020 | $267,000 | -9.5% | 6,343 | -1.6% | 0.00% | – |
| Q3 2020 | $295,000 | -35.6% | 6,443 | -29.4% | 0.00% | – |
| Q2 2020 | $458,000 | -26.5% | 9,129 | -24.7% | 0.00% | -100.0% |
| Q1 2020 | $623,000 | -16.6% | 12,121 | +0.2% | 0.00% | 0.0% |
| Q4 2019 | $747,000 | +2.9% | 12,092 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $726,000 | -28.8% | 12,092 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,020,000 | -50.0% | 12,092 | -50.7% | 0.00% | 0.0% |
| Q1 2019 | $2,039,000 | +135.7% | 24,503 | +100.6% | 0.00% | 0.0% |
| Q4 2018 | $865,000 | -17.1% | 12,214 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $1,044,000 | -38.7% | 12,214 | -16.8% | 0.00% | -50.0% |
| Q2 2018 | $1,702,000 | +6.8% | 14,683 | -25.5% | 0.00% | 0.0% |
| Q1 2018 | $1,594,000 | – | 19,697 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 1,055,719 | $35,367,000 | 12.68% |
| GREAT POINT PARTNERS LLC | 828,253 | $27,746,000 | 5.70% |
| McClain Value Management LLC | 116,153 | $3,891,000 | 4.80% |
| Stonepine Capital Management, LLC | 231,913 | $7,769,000 | 4.63% |
| ARMISTICE CAPITAL, LLC | 228,000 | $7,638,000 | 1.81% |
| Opaleye Management Inc. | 90,000 | $3,015,000 | 1.78% |
| Matarin Capital Management, LLC | 257,268 | $8,618,478,000 | 0.97% |
| HAYS ADVISORY LLC | 116,939 | $3,917,000 | 0.87% |
| Granahan Investment Management | 496,025 | $16,617,000 | 0.57% |
| AlphaMark Advisors, LLC | 33,000 | $1,106,000 | 0.57% |